Seminar: Clinical Pharmacology & Human ADME Studies: A Roadmap to Market

Join us for a scientific seminar and networking lunch focused on accelerating clinical pharmacology packages for successful NDA submissions. 

We’ll discuss how integrated program design and end-to-end delivery can reduce the need for multiple vendors—especially for complex studies such as human ADME—while providing the scientific expertise to support decision-making.

You’ll hear how our Synthesis-to-Clinic® approach has delivered human ADME data for 15 years—covering radiosynthesis, drug product manufacture, clinical delivery, mass balance, and metabolite profiling, often under a single contract. We’ll also show how Translational Pharmaceutics® can enable integrated ADME studies alongside broader development timelines, including Phase II POC.

We’ll also outline how to build a fit-for-purpose drug–drug interaction (DDI) strategy—from early risk assessment and in-silico work to efficient study designs, including multi-interaction and cocktail studies. Finally, we will provide a short update on the UK as a clinical research centre, including key data on regulatory approval timelines for Phase I trials.

Through case studies and expert discussion, you’ll see how Quotient Sciences can act as an extension of your team—bringing practical insight as well as delivery capability. 

Space is limited! Register your interest to attend our seminar. If you have any questions or difficulty registering, reach out to [email protected].

Register now

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.